Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.62 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22526656 | 1.00 | CRBN (0.62) | CRBNDDB1GSPT1 | |
| SCHEMBL23832581 | 0.95 | CRBN (0.60) | CRBNDDB1GSPT1 | |
| SCHEMBL23832518 | 0.94 | CRBN (0.59) | CRBNDDB1GSPT1 | |
| SCHEMBL23842395 | 0.93 | CRBN (0.58) | CRBNDDB1GSPT1 | |
| SCHEMBL30289457 | 0.93 | CRBN (0.58) | CRBNDDB1GSPT1 | |
| SCHEMBL23540810 | 0.93 | CRBN (0.56) | CRBNDDB1GSPT1 | |
| SCHEMBL26206078 | 0.92 | CRBN (0.56) | CRBNDDB1GSPT1 | |
| SCHEMBL21070678 | 0.91 | CRBN (0.57) | CRBNDDB1GSPT1 | |
| SCHEMBL23842106 | 0.91 | DDB1 (0.64) | CRBNDDB1 | |
| SCHEMBL29347190 | 0.89 | CRBN (0.54) | CRBNDDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| US-12077555-B2 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-4255568-A1 | NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF | Baylor College of Medicine (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2023019166-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| US-11485750-B1 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| WO-2022120118-A1 | NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CRBN 171/4885DDB1 3993/4885GSPT1 2739/4885 |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CRBN 171/4885DDB1 3993/4885GSPT1 2739/4885 |
| US-12077555-B2 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | CRBN 171/4885DDB1 3993/4885GSPT1 2739/4885 |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CRBN 171/4885DDB1 3993/4885GSPT1 2739/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CRBN 171/4885DDB1 3993/4885GSPT1 2739/4885 |
| US-11485750-B1 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | CRBN 171/4885DDB1 3993/4885GSPT1 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.